Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2025—TITAN, a multimodal whole slide foundation model, outperforms existing slide encoders in various diagnostic and prognostic tasks, including rare disease classification. While promising, TITAN’s limitations, such as partial image representation and domain shift, necessitate further validation and workflow integration before clinical use.
January 2026—Two studies investigated the use of DNA methylation patterns and sex-specific gene expression in neuroendocrine neoplasms (NEN) and Alzheimer disease, respectively.
January 2026—The CAP Council on Informatics and Pathology Innovation (CIPI) launched the CIPI Connections podcast, focusing on informatics in pathology. The podcast, featuring episodes on various topics, aims to educate and introduce listeners to pathology innovators and thought leaders.
January 2026
Q. What is the CAP’s stance on antibody identification software, which is available via subscription, middleware, or an open-source platform? Read answer.
Q. Can toxicology testing be performed on a person who has been deceased for two years? Read answer.
January 2026—The CAP released a guideline for amyloidosis lab workup, recommending Congo red staining for amyloid detection and mass spectrometry for fibril protein typing. The guideline emphasizes the importance of accurate and timely identification of amyloid fibril types for effective treatment.
April 2025—CAP TODAY publisher Bob McGonnagle spoke with Anthony Alburo, MBA, market development manager, diagnostics, Tosoh Bioscience, Melanie Samko, director of marketing, Tosoh Bioscience, and Carrie Pruett, MLS(ASCP)CM, laboratory quality and compliance manager at Illinois CancerCare. Anthony Alburo opens the conversation.
Anthony Alburo: Tosoh Bioscience has a longstanding legacy in immunoassay diagnostics and HPLC [high-performance liquid chromatography] technology. Our immunoassay platforms support comprehensive cancer care with reimbursable tests for oncology, endocrinology, reproductive health, and chronic disease management. Our HPLC column solution has set the standard in A1C testing, a key factor in managing diabetes, which can intersect with cancer treatment. We remain committed to advancing laboratory science to support clinicians and patients at every stage of care.
I’m honored to introduce Melanie Samko, our director of marketing, who brings not only a deep expertise in health care marketing but also a deep personal perspective: She is a breast cancer survivor. Her journey highlights the real-world impact of early detection, diagnostic accuracy, and patient advocacy. Carrie Pruett, MLS(ASCP)CM, laboratory quality and compliance manager at Illinois CancerCare, which recently merged with the US Oncology Network, has extensive expertise in laboratory operations and compliance. She will provide invaluable insights into the challenges and advancements in oncology diagnostics. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by Tosoh Bioscience in recognition of National Cancer Prevention Month.
December 2024—There is no disguising the enthusiasm—not to mention expertise—that David Miklos, MD, PhD, brings to the topic of chimeric antigen receptor T-cell therapies. CAR T-cell products have been strikingly effective in treating large B-cell lymphoma and multiple myeloma, as well as other hematologic malignancies such as acute lymphoblastic leukemia, follicular lymphoma, and mantle cell lymphoma. Sounding equal parts life coach and physician, Dr. Miklos sees nearly limitless potential in this immunotherapy, which entails genetically engineering T cells to express engineered molecules that can recognize and bind to specific antigens on cancer cells. “So much is possible,” he says. “Our little minds are limiting this, not the potential of science. There are a lot of obvious and mind-blowingly effective strategies that are just coming home to roost. We have really blown open the opportunity to advance therapies more quickly, to apply multipronged approaches using logic loops that are essentially programmed into a cell. It’s really exciting.”
December 2024—On the heels of the publication of a joint consensus recommendation on DPYD genotyping, setting out what variants to test for, two experts who have studied the use of DPYD genotyping shed light in CAP TODAY interviews on its importance and its real-world impact.
December 2024—The new edition of the CAP accreditation program checklists will contain revised requirements for the qualification of laboratory directors, technical and general supervisors, technical and clinical consultants, and moderate- and high-complexity testing personnel.
December 2024—Digital pathology in 2024—what’s the sentiment, the pace, the holdup, the worry? Five people spoke online with CAP TODAY publisher Bob McGonnagle on Oct. 9 about the state of play as the end of the year neared.
